A Anvisa (Agencia Nacional de Vigilância Sanitária) anunciou, na manhã dessa quinta-feira (29), a aprovação de cinco novos medicamentos com GLP-1. As canetas emagrecedoras à base de liraglutida e semaglutida estão ligadas ao tratamento de diabetes e obesidade ao controlar a glicose no sangue e o apetite.

As canetas emagrecedoras chegaram ao Brasil e fevereiro de 2016, após a Anvisa aprovar o uso de medicamentos com liraglutida (inicialmente com o medicamento Saxenda para o controle crônico do peso). Desde então, a Anvisa já aprovou 20 canetas em 2026.

Confira abaixo as canetas aprovadas e suas indicações:

• Aribet (liraglutida): indicado para tratamento de diabetes. Registro concedido à empresa Farma Vision Importação e Exportação de Medicamentos Ltda, com fabricação da empresa indiana Biocon
• Lyrza (liraglutida): indicado para tratamento de obesidade, em conjunto com exercícios físicos e mudança na alimentação. Registro concedido à empresa Farma Vision Importação e Exportação de Medicamentos Ltda, com fabricação da empresa indiana Biocon

• Wylovol (liraglutida): indicado para tratamento de obesidade, em conjunto com exercícios físicos e mudança na alimentação. Registro concedido à empresa Farma Vision Importação e Exportação de Medicamentos Ltda, com fabricação da empresa indiana Biocon

• Embeltah (semaglutida): indicado para tratamento de diabetes. Registro concedido à empresa Dr.Reddys Farmacêutica do Brasil Ltda, com fabricação da empresa indiana OneSource Specialty

• Sevema (semaglutida): indicado para tratamento de diabetes- registro da empresa Aché Laboratórios Farmacêuticos S.A, com fabricação da empresa indiana OneSource Specialty

Anvisa aprova mais cinco canetas emagrecedoras | CNN NOVO DIA

Entenda mais sobre os medicamentos

A semaglutida é um medicamento que funciona como se fosse uma “cópia” melhorada de um hormônio que o nosso próprio corpo produz no intestino, chamado GLP-1. Ele atua no cérebro, fornecendo sensação de saciedade; no estômago, reduzindo a velocidade da digestão e impedindo que o estômago esvazie muito rápido; e no pâncreas, ajudando a regular os níveis de açúcar no sangue, com aplicações semanais.

A liraglutida é outro medicamento da mesma família da semaglutida (os chamados análogos do GLP-1), mas pertence a uma geração anterior. Ele também atua no cérebro, estômago e intestino, mas com aplicações diárias.

Canetas emagrecedoras: estudo lista novos possíveis efeitos colaterais

*Sob supervisão de Carolina Figueiredo

• Telehealth company Ro is launching an AI agent trained on customer data.
• The agent can recommend prescription changes, schedule deliveries, or write memos to a doctor.
• Eventually, Ro hopes to make it a "quarterback" for care. Will it improve outcomes?

Wouldn't it be great if we all had a little, digital minion handling all the small back-and forth chores of our medical care?

On Thursday, Ro is officially announcing the launch of its new AI health agent, designed to do more than a health inquiry on ChatGPT. It's the latest in a long lineup of healthcare agents — from insurers, telehealth providers, electronic health record systems, and regular chatbots — promising to cut down patient wait times, increase access to care, and improve personalized health recommendations with AI.

Ro CEO and co-founder Zach Reitano gave Business Insider an exclusive preview of Ro's new agent, called Robin, showing us how the tool could be used to perform routine tasks like managing side effects, meal planning, or making medication changes.

A founder's mission: disrupt healthcare delivery with AI agents

Reitano said this isn't just about making life more convenient for Ro's current subscribers, though that is the starting point. His long-term goal is to identify pain points where Ro customers need to seek out specialists for common conditions or prescriptions, then start offering more and more of that care in-house, becoming your go-to "quarterback" for the entire American healthcare system.

"I think it's very unlikely to me that one provider or one system handles 100% of someone's care, but I do think it is quite likely that there is one place in someone's life that serves as that quarterback and helps them navigate the rest of the healthcare system," he said. "We hope to be able to just continue to increase those concentric circles, where instead of saying you might be better suited outside of the Ro ecosystem, we would want you to be better suited in it."

When I asked him if his "ultimate goal" is to become a full-service virtual clinic, he said yeah, that's the hope.

For now, Ro's AI agent uses information that's already stored in the app, including notes from doctors, patient feedback, prescriptions, and Apple Health data to try to personalize recommendations for medication changes, dosing tweaks, or habits that might improve side effects.

It's meant to be more instinctively knowledgeable about your health than ChatGPT — requiring less prompting or uploading health data, since it already has information about patients on file. It can suggest a change in medication, and then go ahead and write a first draft of a note to your doctor, if you want it to.

"The underlying premise is: If I have your underlying health information, I can provide more informed and better things, better recommendations," telehealth researcher Dr. Ateev Mehrotra, chair of the health policy department at Brown University, said.

Only issue is, we don't yet know if that's true.

"People are giving up a lot of data for this, and so you really have to say that it truly is going to give you something," Mehrota added. "It sounds cool in theory, I'm not saying it's a bad idea. I would love some evidence before millions of Americans start doing this."

Personally, Mehrotra says he'd be much more likely to try out one of the AI agents embedded into an official electronic health record system, which has access to everything he's told his regular doctors and specialists within a specific hospital system and which — critically — has to abide by strict privacy rules. (Business Insider did not see Ro's privacy policy for Robin.)

"My health system doesn't have the weird financial incentives that we're worried about with Ro," he said. "More data, less financial incentives, I might use that."

Reitano says ultimately, it's not in his company's interests to go after short-term profits at the expense of a good patient experience.

"We fight for patients, and we serve you, and if we don't, then we go out of business," he said.